Topic: psoriatic arthritis
As the psoriatic arthritis field heats up, Novartis has added some new data to its Cosentyx label it hopes can stretch out the drug’s lead.
With new nods for Pfizer’s Xeljanz and AbbVie’s upadacitinib coming, makers of anti-inflammatory drugs will be feeling the heat from JAK inhibitors.
Eli Lilly's newer drugs are pumping out sales, especially its lead growth driver Trulicity, a diabetes drug. So much so, the company hiked its 2018 guidance.
For the second straight week, there’s a new psoriatic arthritis drug on the block.
Eli Lilly’s Taltz officially has a new arena to challenge Novartis’ Cosentyx.
Novartis’ Cosentyx currently leads a crop of immunology meds from a who’s who of Big Pharma. And the company intends to keep it that way.
Eli Lilly is counting on psoriasis med Taltz to drive U.S. volume growth. But lately, that growth has stalled.
Novartis has already featured real patients in Cosentyx psoriasis ads. Now, as it features the med in psoriatic arthritis, it’s going a similar route.
With its latest DTC work for Stelara, J&J is pivoting to push for growth in Crohn's disease instead of psoriasis.